Gout Study Group: Update on hyperuricemia and gout

Joint Bone Spine

Volumn 76, Issue 4, 2009, Pages 444-446

  Terkeltaub, Robert ^a   Zelman, David ^b   Scavulli, John ^c   Perez Ruiz, Fernando ^d   Lioté, Frédéric ^e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c Hospital de Cruces ^*  (United States)

^d HOSPITAL DE CRUCES   (Spain)

^e HÔPITAL LARIBOISIÈRE   (France)

^f INSERM   (France)

Author keywords

Allopurinol; Anti IL 1 antibody; Comorbidities; Diet; Febuxostat; Gout; Metabolic syndrome; Steroids; Uricase; Uricosurics

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMLODIPINE; ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; COLCHICINE; ERYTHROMYCIN; ESTROGEN; ETHAMBUTOL; FEBUXOSTAT; FENOFIBRATE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INSULIN; LEFLUNOMIDE; LOSARTAN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PYRAZINAMIDE; SALICYLIC ACID; URIC ACID;

CHRONIC DISEASE; COMORBIDITY; DIET RESTRICTION; DRUG MEGADOSE; EUROPE; GOUT; HUMAN; HYPERURICEMIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; PREVALENCE; SHORT SURVEY; UNITED STATES; URIC ACID BLOOD LEVEL;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLCHICINE; DIET; EUROPE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; LIFE STYLE; PREDNISONE; PREVALENCE; THIAZOLES; UNITED STATES; URIC ACID;

EID: 67649982872     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.05.006     Document Type: Short Survey

References (10)

1. Briesacher B.A., Andrade S.E., Fouayzi H., et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28 (2008) 437-443
2. Choi H.K., Ford E.S., Li C., et al. Prevalence of the metabolic syndrome in patients with Gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 57 (2007) 109-115
3. Singh J.A., and Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilization in US Veterans. Ann Rheum Dis 67 (2008) 1310-1316
4. Hak A.E., and Choi H.K. Lifestyle and gout. Curr Opin Rheumatol 20 (2008) 179-186
5. Zhang W., Doherty M., Bardin T., et al. EULAR Evidence based recommendations for gout. Parts I and II. Ann Rheum Dis 65 (2006) 1301-1324
6. Perez-Ruiz F., and Schlesinger N. Management of gout. Scand J Rheumatol 37 (2008) 81-89
7. Terkeltaub R., Furst D., Bennett K., et al. Low dose (1.8 mg) vs high dose (4.2 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum Suppl. S879 (2008) [abstract 1944]
8. Perez-Ruiz F., and Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. Arthritis Rheum 57 (2007) 1324-1338
9. Sakhaee K., Adams-Huet B., Moe O.W., et al. Pathophysiological basis for normouricosuric uric acid nephrolithiasis. Kidney Int 62 (2002) 971-979
10. Perez-Ruiz F. Treating to target: a strategy tocure gout. Rheumatology, in press.